NOTICE

NOTICE is hereby given that the 33rd Annual General Meeting of the Medicamen Biotech Limited will be held on Saturday, the 26th day of September 2026 at 12.00 Noon through Video Conference/Other Audio Video Means (VC/OAVM) to transact the following business. The venue of the meeting shall be deemed to be the Registered Office of the Company at 1506, Chiranjiv Tower, 43, Nehru Place, New Delhi-110019.

ORDINARY BUSINESS

1. **TO RECEIVE, CONSIDER AND ADOPT THE AUDITED STANDALONE FINANCIAL STATEMENTS OF THE COMPANY FOR THE FINANCIAL YEAR ENDED 31 MARCH 2026 AND THE REPORTS OF THE BOARD OF DIRECTORS AND STATUTORY AUDITOR THEREON**

   "**RESOLVED THAT** the audited standalone financial statements of the Company for the financial year ended 31 March 2026 and the reports of the Board of Directors and Statutory Auditor thereon as circulated to the members with the notice of the Annual General Meeting, be and are hereby received, considered and adopted."

2. **TO RECEIVE, CONSIDER AND ADOPT THE AUDITED CONSOLIDATED FINANCIAL STATEMENTS OF THE COMPANY FOR THE FINANCIAL YEAR ENDED 31 MARCH 2026 AND THE REPORT OF THE STATUTORY AUDITOR THEREON**

   "**RESOLVED THAT** the audited consolidated financial statements of the Company for the financial year ended 31 March 2026 and the report of Statutory Auditor thereon, as circulated to the members with the notice of the Annual General Meeting, be and are hereby received, considered and adopted."

3. **TO DECLARE DIVIDEND ON EQUITY SHARES**

   "**RESOLVED THAT** the final dividend of ₹ 1 /- (Rupees One only) per Equity Shares (i.e. 10% on the face value of 10/-), as recommended by the Board of Directors, for the financial year ended 31 March 2026, be and is hereby declared."

4. **TO RE-APPOINT MR SURESH KUMAR SINGH (DIN: 00318015) AS A DIRECTOR LIABLE TO RETIRE BY ROTATION**

   "**RESOLVED THAT** pursuant to the applicable provision(s) of the applicable law(s) (including any amendments thereto or re-enactment thereof for the time being in force), in accordance with the Articles of Association of the Company and upon recommendation of the Nomination and Remuneration Committee and the Board of Directors, **Mr Suresh Kumar Singh (DIN: 00318015),** Non-Executive Director, who retires by rotation and being eligible has offered himself for re-appointment, be and is hereby re-appointed as a Director of the Company, liable to retire by rotation."

5. **TO RE-APPOINT MR SANJAY BANSAL (DIN: 00121667) AS A DIRECTOR LIABLE TO RETIRE BY ROTATION**

   "**RESOLVED THAT** pursuant to the applicable provision(s) of the applicable law(s) (including any amendments thereto or re-enactment thereof for the time being in force), in accordance with the Articles of Association of the Company and upon recommendation of the Nomination and Remuneration Committee and the Board of Directors, **Mr Sanjay Bansal (DIN: 00121667),** Non-Executive Director, who retires by rotation and being eligible has offered himself for re-appointment, be and is hereby re-appointed as a Director of the Company, liable to retire by rotation."

SPECIAL BUSINESS

6. **RATIFICATION OF REMUNERATION OF COST AUDITORS**

   To consider and if thought fit, to pass the following resolution as an Ordinary Resolution:

   "**RESOLVED THAT** pursuant to the provisions of Section 148(3) and other applicable provisions, if any, of the Companies Act, 2013 [including any statutory modification(s) or re-enactment(s) thereof for the time being in force] read with the Companies (Audit and Auditors) Rules, 2014, as amended from time to time, the Company hereby ratifies the remuneration of ₹ 2,00,000/- plus applicable taxes and out-of-pocket expenses incurred in connection with the cost audit payable to SPB & Co., Cost Accountants (Firm Registration No. 102586), who are appointed by the Board of Directors of the Company on the recommendation of the Audit Committee, as Cost Auditors of the Company to conduct audit of the cost records maintained by the Company as prescribed under the Companies (Cost Records and Audit) Rules, 2014, as amended from time to time, for the financial year ending 31 March 2027.

   RESOLVED FURTHER THAT the Board of Directors of the Company be and is hereby authorised to do all such acts, deeds, matters and things as may be necessary, expedient and desirable for the purpose of giving effect to this resolution."

7. **TO APPROVE MATERIAL RELATED PARTY TRANSACTIONS WITH SHIVALIK RASAYAN LIMITED (HOLDING COMPANY)**

   To consider and, if thought fit, to pass the following resolution as an Ordinary Resolution-

   "RESOLVED THAT pursuant to the provisions of Section 188 and other applicable provisions, if any, of the Companies Act, 2013 ("the Act") read with the

Rules framed thereunder, the applicable provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations"), including Regulation 23 thereof, the SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated 30 January 2026, the Company's Policy on Related Party Transactions, and such other applicable laws, statutory modifications or re-enactments thereof for the time being in force, and subject to such approvals, permissions and sanctions as may be necessary, the consent of the Members of the Company be and is hereby accorded to enter into and/or continue to enter into one or more contract(s), arrangement(s), agreement(s), transaction(s) and/or Material Related Party Transaction(s), whether by way of individual transaction(s) or a series of transaction(s), with Shivalik Rasayan Limited, Holding Company of the Company and a Related Party within the meaning of Section 2(76) of the Companies Act, 2013 and Regulation 2(1)(zb) of the SEBI Listing Regulations, for procurement of Active Pharmaceutical Ingredients (APIs), research and development support, technical support, product development, process optimisation and such other products and/or services as may be required by the Company from time to time in the ordinary course of business, on an arm's length basis, for an aggregate amount not exceeding ₹30,00,00,000 (Rupees Thirty Crores only) during the period commencing from the date of approval of the Members until the conclusion of the next Annual General Meeting of the Company or one year from the date of this approval, whichever is earlier.

RESOLVED FURTHER THAT the Members hereby note that the aforesaid Material Related Party Transactions have been reviewed and recommended by the Audit Committee and approved by the Board of Directors of the Company, after considering, inter alia, the nature of the transactions, business rationale, commercial terms, pricing methodology, materiality, necessity, benefit to the Company and compliance with applicable legal and regulatory requirements and the Board recommends the Resolution for approval of the Members.

RESOLVED FURTHER THAT the aforesaid transactions shall be undertaken in the ordinary course of business and on an arm's length basis and the pricing mechanism shall be based on prevailing market prices, comparable uncontrolled prices, commercial quotations, negotiated contractual terms and such other pricing methodologies as may be considered appropriate by the Management and the Audit Committee from time to time.

RESOLVED FURTHER THAT the Board of Directors of the Company (hereinafter referred to as the "Board", which expression shall include any Committee thereof, including the Audit Committee, or any Director(s), Key Managerial Personnel or officer(s) authorised by the Board) be and is hereby authorised to negotiate, finalise, execute, amend, modify, renew, supplement, continue, extend, assign, novate or terminate the agreements, contracts, purchase orders, work orders, arrangements and other documents relating to the aforesaid transactions and to determine the detailed terms and conditions thereof, including pricing, quantity, delivery schedules and other commercial terms, as may be considered necessary or expedient in the best interests of the Company.

RESOLVED FURTHER THAT the Board be and is hereby authorised to do all such acts, deeds, matters and things and to execute all such documents, writings, declarations, confirmations, forms and filings as may be necessary, proper, desirable or expedient to give effect to this Resolution and to settle any question, difficulty or doubt that may arise in this regard without requiring any further approval of the Members.

RESOLVED FURTHER THAT all acts, deeds, matters and things already undertaken by the Board of Directors, the Audit Committee or any authorised officer of the Company in connection with the aforesaid transactions be and are hereby ratified, confirmed and approved to the extent permissible under applicable law.

8. TO APPROVE MATERIAL RELATED PARTY TRANSACTIONS WITH MEDICAMEN LIFE SCIENCES PRIVATE LIMITED (SUBSIDIARY COMPANY)

To consider and, if thought fit, to pass the following Resolution as an Ordinary Resolution:

"**RESOLVED THAT** pursuant to the provisions of Section 188 and other applicable provisions, if any, of the Companies Act, 2013 ("the Act") read with the Companies (Meetings of Board and its Powers) Rules, 2014, Regulation 23 and other applicable provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations"), the SEBI Master Circular No.HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated 30 January 2026, the Company's Policy on Related Party Transactions and such other applicable laws, rules, regulations, circulars and guidelines, including any statutory modification(s) or re-enactment(s) thereof for the time being in force, and subject to such approvals, permissions and sanctions as may be necessary, consent of the Members of the Company be and is hereby accorded to enter into and/or continue to enter into one or more contract(s), arrangement(s), agreement(s), transaction(s) and/or Material Related Party Transaction(s), whether by way of an individual transaction or a series of transactions, with Medicamen Life Sciences Private Limited, a Subsidiary of the Company and a Related Party within the meaning of Section 2(76) of the Companies Act, 2013 and Regulation 2(1)(zb) of the SEBI Listing Regulations, for sale and supply of pharmaceutical formulations, contract manufacturing arrangements, trading of pharmaceutical products, marketing and distribution support, warehousing and logistics support and such other products and/or services as may be mutually agreed from time to time, in the ordinary course of business and on an arm's length basis, for an aggregate amount not exceeding ₹30,00,00,000 (Rupees Thirty Crores only) during the period commencing from the date of approval of the Members until the conclusion of the next Annual General Meeting of the Company or one year from the date of this approval, whichever is earlier.

RESOLVED FURTHER THAT the Members hereby note that the proposed Material Related Party Transactions have been reviewed and recommended by the Audit Committee and approved by the Board of Directors of the Company after considering the nature of the transactions, commercial rationale, pricing methodology, materiality, necessity and overall benefit to the Company and accordingly the Board recommends the Resolution for approval of the Members.

RESOLVED FURTHER THAT the aforesaid transactions shall be undertaken in the ordinary course of business and on an arm's length basis and the pricing mechanism shall be determined having regard to prevailing market prices, comparable uncontrolled prices, commercial quotations, negotiated contractual terms, volume of transactions, product specifications and such other commercially accepted parameters as may be considered appropriate by the Management and reviewed by the Audit Committee from time to time.

RESOLVED FURTHER THAT the Board of Directors of the Company (hereinafter referred to as the "Board", which expression shall include any Committee thereof, including the Audit Committee, or any Director(s), Key Managerial Personnel or officer(s) authorised by the Board) be and is hereby authorised to negotiate, finalise, execute, amend, modify, renew, supplement, continue, extend, assign, novate or terminate the agreements, contracts, purchase orders, work orders, arrangements and other documents relating to the aforesaid transactions and to determine the detailed terms and conditions thereof, including pricing, quantity, specifications, delivery schedules and other commercial terms, as may be considered necessary or expedient in the best interests of the Company.

RESOLVED FURTHER THAT the Board be and is hereby authorised to do all such acts, deeds, matters and things and to execute all such documents, writings, declarations, confirmations, forms and filings as may be be necessary, proper, desirable or expedient to give effect to this Resolution and to settle any question, difficulty or doubt that may arise in this regard without requiring any further approval of the Members.

RESOLVED FURTHER THAT all acts, deeds, matters and things already undertaken by the Board of Directors, the Audit Committee or any authorised officer of the Company in connection with the aforesaid transactions be and are hereby ratified, confirmed and approved to the extent permissible under applicable law.

NOTES:

1. The Ministry of Corporate Affairs ("MCA") has, vide its Circular nos. 20/2020, 14/2020, 17/2020, 02/2021,02/2022, 10/2022, 09/2023, 09/2024, the latest being 03/2025 dated 22nd September, 2025 and the Securities and Exchange Board of India ('SEBI') vide its circular no. SEBI/HO/CFD/CFD-PoD-2/P/CIR/2024/133 dated 03 October 2024 and other applicable circulars issued in this regard, (hereinafter collectively referred to as "the Circulars"), have permitted holding of the Annual General Meeting ("AGM") through Video Conferencing ("VC"). Hence, the AGM of the Company is being held through VC. The deemed venue for the AGM shall be the registered office of the Company, i.e. Medicamen Biotech Limited 1506, Chiranjiv Tower, 43, Nehru Place, New Delhi -110019
2. The Notice of 33rd AGM ("Notice") was approved by the Board of Directors at its meeting held on 14 August 2026 and the Company Secretary was authorised to issue the Notice.
3. The members can join the AGM through VC 15 minutes before the scheduled time or any time thereafter till the conclusion of the meeting by following the procedure mentioned in the Notice. The facility of participation at the AGM through VC will be made available for 1,000 members on a first-come-first-serve basis. This will not include large shareholders (holding 2% or more shareholding), promoters, institutional investors, directors, key managerial personnel and auditors, among others, who are allowed to attend the AGM without restriction on account of a first-come first-serve basis and can connect with the Company at cs@medicamen.com.
4. The Board of Directors of the Company has appointed Mr Manoj Kumar Jain, Practicing Company Secretary, (Membership No. 5832 and CP No. 5629), Proprietor of M/s. AMJ & Associates., of F-2, Plot No. 299, Sector-4, Vaishali, Ghaziabad-UP-201010 as the Scrutiniser to scrutinise the remote electronic voting ("e-voting") process and e-voting in a fair and transparent manner.
5. Since this AGM is being held through VC, physical attendance of members has been dispensed with. Accordingly, the facility for appointment of proxies by the members will not be available for the AGM. Members attending the AGM through VC will be counted for the purpose of reckoning the quorum under Section 103 of the Companies Act, 2013 ("Act").
6. Members of the Company under the category of Institutional Investors are encouraged to attend and vote in the AGM. In compliance with the provisions of Section 113 of the Act, Corporate/Institutional members (i.e. other than Individuals, HUF, NRI, etc.) are required to send scanned certified true copy (PDF/ JPG format) of the board resolution/ power of attorney/ authority letter etc. to the Scrutiniser at e-mail id: amj.associates@gmail.com with copy marked to investor.helpdesk@in.mpms.mufg.com to attend the AGM through VC and to vote through remote e-voting.
7. In compliance with the Circulars, Notice along with the Annual Report 2025-26 is being sent only through electronic mode to those members whose email addresses are registered with the Company/ National Securities Depository Limited and Central Depository Services (India) Limited ('Depositories')/ MUFG Intime India Private Limited ("RTA").
8. A letter containing the weblink and QR code for accessing the Notice and Annual Report for the 2025-26 will be sent to those shareholders who have not registered their email address with the Company/ Depositories/RTA.
9. Since the AGM will be held through VC, the route map, proxy form and attendance slip are not applicable and therefore not attached to this Notice.
10. Members will be provided with the facility of e-voting and attending the AGM through VC by the MUFG Intime India Private Limited ("MUFG").
11. Notice of the AGM along with the Annual Report 2025-26 is available on the website of the Company at www.medicamen.com, on websites of the Stock Exchanges i.e. BSE Limited and National Stock Exchange of India Limited at www.bseindia.com and www.nseindia.com, respectively and also on website of MUFG Intime India Private Limited ("MUFG").
12. The Register of Directors and Key Managerial Personnel and their shareholding, maintained under Section 170 of the Act, the Register of Contracts or Arrangements in which the directors are interested, maintained under Section 189 of the Act, would be available for inspection in electronic mode by the members during the AGM. All documents referred to in the Notice will also be available for inspection in electronic mode without any fee by the members from the date of circulation of this Notice up to the date of AGM on Saturday, 26 September 2026 during business hours. Members who wish to inspect such documents may send a request on the email id cs@medicamen.com at least one working day before the date on which they intend to inspect the document.
13. The explanatory statement pursuant to Section 102 of the Act forms part of the Notice. As required under the Secretarial Standard – 2 and Regulation 36(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations,

2015 ("SEBI Listing Regulations") the relevant information of the director seeking re-appointment is attached as **Annexure I**.

14. Important instruction for shareholders holding shares in physical form.

a. SEBI, vide its circular no. SEBI/HO/MIRSD/MIRSD_RTAMB/P/CIR/2022/8 dated 25 January 2022 has mandated the listed company to issue the securities in dematerialised form only while processing investor service requests viz. issue of duplicate securities certificate; renewal/exchange of securities certificate; endorsement; sub-division/ splitting of securities certificate; consolidation of securities certificates/folios; transmission and transposition**.**

As per SEBI circular no. HO/38/13/(3)2026-MIRSDPOD/I/3763/2026 dated 30 January 2026, the requirement of issuance of a Letter of Confirmation ("LOC") by the Company/RTA has been dispensed with for the aforesaid investor service requests with effect from 02 April 2026. Accordingly, securities will be credited directly to the shareholder's demat account upon submission of latest Client Master List with duly filled demat conversion request form to the RTA. In view of the same and to eliminate the risks associated with physical shares and to avail various benefits of dematerialisation, members are advised to dematerialise the shares held by them in physical form. Members can contact the Company or RTA, for assistance in this regard.

b. Members are requested to update their email address, choice of nomination and KYC records by submitting duly filled and signed relevant form along with the relevant proofs listed in the forms, to MUFG Intime India Private Limited, Registrar and Share Transfer Agent. Alternatively, members can also send digitally signed documents from their registered email address at investor.helpdesk@in.mpms.mufg.com.Details of the relevant forms are provided herein below:

Form	Particulars
ISR-1	Request for registering PAN, KYC or changes/updating thereof
ISR-2	Confirmation of signature of the securities holder by the banker
ISR-3	Declaration form for holders of physical securities in listed companies to opt out of nomination
ISR-4	Request for issue of Duplicate Certificate and other Service Requests
ISR-5	Request for Transmission of Securities by Nominee or Legal Heir
SH-13	Nomination form
SH-14	Cancellation or variation of Nomination

15. Members holding shares in demat form who wish to update any of the details mentioned above can contact their depository participant for the same.

16. SEBI has introduced Online Dispute Resolution ("ODR") portal for dispute resolution in addition to the existing SEBI Complaints Redress System ("SCORES") platform, which can be utilised by the investors and the Company for dispute resolution. The SMART ODR Portal can be accessed at: https://smartodr.in/login.

17. Record Date and Dividend:

i. The dividend for the year ended 31 March 2026 as recommended by the Board, upon declaration at the AGM, will be paid to those members whose names will appear in the Register of Members on the record date i.e., as at the close of business hours on Saturday, 19 September 2026. With effect from 01 April 2024, as per the SEBI Circular dated 10 June 2024 read with SEBI Master Circular dated 06 February 2026, shareholders holding shares in physical form and who have not completed any of their KYC, will be eligible to receive dividend, only upon completion of KYC. Members are therefore advised to update their KYC details on priority, if not done already, following the procedure as mentioned in point 14(ii).

ii. Members holding shares in dematerialised form may please note that, in accordance with the direction of the Stock Exchanges, bank details as furnished by the respective depositories will be used for the purpose of distribution of dividend.

iii. Pursuant to the provisions of Sections 124 and 125 of the Act and the Investor Education and Protection Fund Authority (Accounting, Audit, Transfer and Refund) Rules, 2016 ("IEPF Rules") dividends that remain unpaid or unclaimed for a period of seven year or more, are mandatorily required to be transferred to the Investor Education and Protection Fund ("IEPF"). Accordingly, unpaid or unclaimed dividends up to the financial year 2017-18 have been transferred to the IEPF.

As per the provisions of Section 124(6) of the Act read with the IEPF Rules as amended, all shares in respect of which dividends have remained unclaimed for seven consecutive years or more for the financial year 2017-18 were transferred by the Company to the IEPF in June 2025. The Company had sent individual communications to the concerned shareholders whose shares were liable to be transferred to the IEPF.

Members may note that unclaimed final dividend for the financial year ended 31 March 2019 will become due for transfer to the IEPF on Friday, 25 October 2026. Those members who have not claimed dividend for the said period and also for the subsequent years are requested to claim the dividend. The member can contact our Registrar and Share Transfer Agent, MUFG Intime India Private Limited at investor.helpdesk@in.mpms.mufg.com.Shares Department of the Company at cs@medicamen.com to claim the dividend.

We have uploaded the details of such members on website of the Company, i.e., www.medicamen.com, under the 'Investors section'. Please note that no claim shall lie against the Company in respect of unclaimed dividend and shares transferred to the IEPF pursuant to the said Rules.

As per the provisions of Section 125 of the Act and the IEPF Rules, members whose unclaimed dividend, unclaimed redemption amount of preference shares, unclaimed sale proceeds of fractional shares and equity shares have been transferred to IEPF, may claim the refund by making an application to the IEPF Authority in web form IEPF-5 available on www.mca.gov.in.

TDS on Dividend Amount

18. As per the Income Tax Act, 2025 ("the IT Act"), dividends paid or distributed by the Company is taxable in the hands of the shareholders. Accordingly, companies are required to deduct tax at source from dividends paid to shareholders.

The rate of deduction of tax depends on:

a. Residential status of the shareholder
b. Valid tax registration (PAN or equivalent taxpayer identification)
c. The documents/declarations submitted by the shareholder and accepted by the Company.

For resident individual shareholders:

- As per section 393(1) [Table: Sr. No. 7] of the IT Act, any domestic company making payment to a resident shareholder shall deduct tax 10% at the time of payment of dividend to shareholder if it exceeds Rs 10,000 and who has provided valid PAN. However, on submission of any lower withholding tax certificate under provision of the Act for Tax Year 2026-27, the withholding tax shall be at the rate mentioned in the certificate issued by the Authority.
- As per section 393(4) [Table: Sr. No. 10], no tax shall be deducted if the amount or aggregate of amounts of such dividend distributed or paid or likely to be distributed or paid during the tax year does not exceed ₹ 10,000 and the dividend is paid in any mode other than in cash.
- As per section 393(6) of the IT Act, if shareholder provides duly filed declaration in Form 121 for relevant tax year (T.Y. 2026-27) complete in all respects and all the required eligibility conditions are met then, NIL tax will be deducted at source.
- The new taxation regime under Section 202 of the IT Act is the default tax regime as per Income Tax Provisions. Accordingly, we shall consider the forms for exemption only in cases where estimated total income for individual whose age is below 60 years is <= ₹ 4,00,000 and in case of individual exceeding age of 60 years is <= ₹12,00,000 as per provisions of Section 393(6) of the IT Act.
- In case of invalid or non-availability of PAN, tax will be deducted at the rate of 20%.

For resident shareholders other than individual (HUF/LLP/AOP/Companies/Firm/Trust):

- At 10% on the entire amount of dividend to be received by the shareholder without any threshold. However, on submission of any lower withholding tax certificate or any exemption status under provision of the IT Act obtained by shareholders for Tax Year 2026-27, the withholding tax shall be at the rate mentioned in the certificate issued by the authority.
- In case of invalid or non-availability of PAN, the withholding tax shall be at 20%.
- The aforesaid declarations are to be submitted to cs@medicamen.com

For other category shareholders, viz. Mutual Fund, Insurance Company, Alternate Investment Fund ("AIF") Category I and II, Government (Central/State Government) etc:

In order to provide exemption from withholding the taxes on dividend payable, shareholders are required to provide self-declaration along with their registration with concerned authority about their category, such as:-

- Declaration and registration certificate by shareholder qualifying as Insurer as per Section 2(7A) of the Insurance Act, 1938.
- Declaration and registration certificate by Mutual Fund shareholder eligible for exemption under Schedule VII (Table: S. No. 20 and 21) of the IT Act.
- Declaration and registration certificate by Category I/II AIF registered with SEBI.
- Self-attested copy of valid approval granted by approving authority as per relevant Income Tax Rules of Schedule XI of Act to Recognised Provident Fund / Approved Gratuity Fund/ Approved Superannuation Fund.
- The aforesaid declarations are to be submitted to cs@medicamen.com.

For non-resident shareholders including Foreign Portfolio Investor (“FPI”)/(“FII”) Category:

At 20% (plus applicable surcharge and cess) on the entire amount of dividend to be received by the shareholder without any threshold. However, as per Section 159 of the IT Act, the non-resident shareholder has the option to be governed by the provisions of the Double Tax Avoidance Agreement (tax treaty) between India and the country of tax residence of the shareholder, if they are more beneficial to them. For this purpose, i.e., to avail a lower rate of deduction of tax at source under an applicable tax treaty read with multilateral instruments, if applicable, such non-resident shareholders must provide the following:

- Self-attested copy of the PAN allotted by the Indian Income Tax authorities, if any.
- Self-attested copy of Tax Residency Certificate (“TRC”) obtained from the tax authorities of the country of which the shareholder is resident for Tax Year 2026-27 and containing TRC number if available.
- Self-attested copy of acknowledgement and copy of Form 41 filed online for Tax Year 2026-27 in https://www.incometax.gov.in/iec/foportal/.

Self-declaration, certifying the following points that no PE declaration should cover points given below:

- Non-Resident is and will continue to remain a tax resident of the country of residence during Tax Year 2026-27.
- Non-Resident is eligible to claim the beneficial DTAA rate for the purposes of tax withholding on dividend declared by the Company.
- Non-Resident has no reason to believe that the claim for the benefits of the DTAA is impaired in any manner.
- Non-Resident is the ultimate beneficial owner of the shareholding in the Company and Dividend receivable from the Company.
- Non-Resident does not have a taxable presence or a permanent establishment in India during Tax Year 2026-27.
- The aforesaid declarations are to be submitted to cs@medicamen.com

Note : As per the IT Act and rules thereto, for generating certificate for foreign remittances to non-resident shareholder (i.e., Form 145 and/ or 146), mentioning Tax Identification No. (“TIN”) or equivalent unique identification number is mandatory irrespective whether DTAA benefit claimed or not. Thus request every non-resident shareholder to provide TIN or equivalent unique identification number.

Benefit under Rule 203

If dividend income on which tax has been deducted at source is assessable in the hands of a person other than the shareholder, then declaration needs to be provided by shareholder as per Rule 203 of the Income-tax Rules, 2026. The aforesaid declaration is to be e-mailed to cs@medicamen.com.

General Instructions:

- All the documents submitted by the shareholder will be verified by the Company / its Authorised Representative and the Company will consider the same while deducting appropriate taxes, if they are in accordance with the provisions of the IT Act.
- For resident shareholders, the rate of TDS would not be increased by surcharge and cess. For non-resident shareholders, the rate of TDS would be increased by applicable surcharge and cess.
- The Company shall not obligated to apply the beneficial DTAA rates at the time of withholding tax on the dividend amount. Application of beneficial DTAA rate shall depend upon the completeness and satisfactory review by the Company, of the documents submitted by the non-resident shareholder.
- If for any reason the tax on dividend is deducted at a higher rate for the shareholder, there would still be an option available with the shareholder to file the return of income and claim an appropriate refund, if eligible.
- In the event of any income-tax demand (including interest, penalty etc.) arising from any misrepresentation, inaccuracy or omission of information provided / to be provided by the shareholders, such shareholders will be

responsible to pay and indemnify such income tax demand (including interest, penalty, etc.) and provide the Company with all information / documents that may be necessary and cooperate in any proceedings\ before any income tax/ appellate authority.

- The above withholding tax is in summarised form of law and not detailed analysis nor any tax advice. For detailed tax advice related to their tax matters, shareholders are advised to seek professional guidance.

19. The Chairman authorised the Company Secretary to receive and countersign the scrutiniser's report and declare the results, along with the consolidated scrutiniser's report within the timeframe prescribed under the Act and the SEBI Listing Regulations. The resolutions will be deemed to be passed on the AGM date subject to receipt of the requisite number of votes in favour of the resolutions.

20. The results declared along with the scrutiniser's report will be placed on the website of the Company, i.e., www.medicamen.com, under the 'Investors Section' and on the MUFG Intime India Private Limited's website i.e. https://instavote.linkintime.co.in/. The results will also be disclosed on the stock exchanges.

21. SEBI, vide Circular No. HO/38/13/11(2)2026-MIRSDPOD/I/3750/2026 dated 30 January 2026, has opened a special window to facilitate re-lodgement of transfer and dematerialisation of physical securities. The window will remain open for a period of one year,i.e., from 05 February 2026 to 04 February 2027.

    This special facility will be available for transfer and dematerialisation of physical shares that were sold or purchased prior to 01 April 2019. Additionally, the facility extends to transfer requests that were submitted earlier but were rejected, returned, or not attended to due to deficiencies in documents, process issues, or for any other reason.

    Eligible shareholders who wish to avail the opportunity are requested to submit the requisite documents to MUFG Intime India Private Limited, Registrar and Share Transfer Agent, Noble Heights, 1st Floor, Plot No. NH 2, LSC, C-1 Block, Near Savitri Market, Janakpuri, New Delhi-110058.

    Investors are informed that the securities re-lodged for transfer pursuant to the above circular, shall only be issued in demat form. In case of any queries, shareholders are requested to raise a service request at investor.helpdesk@in.mpms.mufg.com or cs@medicamen.com.

INSTRUCTIONS FOR MEMBERS FOR ATTENDING THE AGM THROUGH VC ARE AS UNDER:

22. The remote e-voting facility will be available during the following voting period:
    i. Commencement of remote e-voting: From 09:00 a.m. IST, Wednesday, 23 September 2026.
    ii. End of remote e-voting: Up to 5:00 p.m. IST, Friday, 25 September 2026.

23. During this period, the shareholders of the Company, holding shares either in physical form or in dematerialised form, as on the cut-off date i.e. 19 September 2026 may cast their vote through remote e-voting. The remote e-voting module shall be disabled by MUFG for voting thereafter and the facility will be blocked forthwith.

24. Remote e-voting instructions for shareholders: In terms of SEBI circular no. SEBI circular no. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11 November 2024, Individual shareholders holding securities in demat mode are allowed to vote through their demat account maintained with Depositories and Depository Participants.

Shareholders are advised to update their mobile number and email Id correctly in their demat accounts to access e-Voting facility.

Login method for Individual shareholders holding securities in demat mode is given below:

Type of shareholders	Login Method
Individual Shareholders holding securities in demat mode with NSDL	**METHOD 1 - NSDL OTP based login** a) Visit URL: https://eservices.nsdl.com/SecureWeb/evoting/evotinglogin.jsp b) Enter your 8 - character DP ID, 8 - digit Client Id, PAN, Verification code and generate OTP. c) Enter the OTP received on your registered email ID/ mobile number and click on login. d) Post successful authentication, you will be re-directed to NSDL depository website wherein you will be able to see e-Voting services under Value added services. Click on "Access to e-Voting" under e-Voting services. e) Click on "MUFG InTime" or "evoting link displayed alongside Company's Name" and you will be redirected to InstaVote

Type of shareholders	Login Method
	METHOD 2 - NSDL IDeAS facility ***Shareholders registered for IDeAS facility:*** a) Visit URL: https://eservices.nsdl.com and click on "Beneficial Owner" icon under "IDeAS Login Section". b) Enter IDeAS User ID, Password, Verification code & click on "Log-in". c) Post successful authentication, you will be able to see e-Voting services under Value added services section. Click on "Access to e-Voting" under e-Voting services. d) Click on "MUFG InTime" or "evoting link displayed alongside Company's Name" and you will be redirected to InstaVote website for casting the vote during the remote e-voting period. ***Shareholders not registered for IDeAS facility***: a) To register, visit URL: https://eservices.nsdl.com and select "Register Online for IDeAS Portal" or click on https://eservices.nsdl.com/SecureWeb/IdeasDirectReg.jsp b) Enter 8-character DP ID, 8-digit Client ID, Mobile no, Verification code & click on "Submit". c) Enter the last 4 digits of your bank account / generate 'OTP' d) Post successful registration, user will be provided with Login ID and password. e) Follow steps given above in points (a-d). Shareholders/ Members can also download NSDL Mobile App "NSDL Speede" facility by scanning the QR code mentioned below for seamless voting experience. Google Play App Store **METHOD 3 - NSDL e-voting website** a) Visit URL: https://www.evoting.nsdl.com b) Click on the "Login" tab available under 'Shareholder/Member' section. c) Enter User ID (i.e., your 16-digit demat account no. held with NSDL), Password/OTP and a Verification Code as shown on the screen & click on "Login". d) Post successful authentication, you will be re-directed to NSDL depository website wherein you will be able to see e-Voting services under Value added services. Click on "Access to e-Voting" under e-Voting services. e) Click on "MUFG InTime" or "evoting link displayed alongside Company's Name" and you will be redirected to InstaVote website for casting the vote during the remote e-voting period.
Individual Shareholders holding securities in demat mode with CDSL	**METHOD 1 - CDSL e-voting page** a) Visit URL: https://www.cdslindia.com. b) Go to e-voting tab. c) Enter 16-digit Demat Account Number (BO ID) and PAN No. and click on "Submit". d) System will authenticate the user by sending OTP on registered Mobile and Email as recorded in Demat Account e) Post successful authentication, user will be able to see e-voting option. The evoting option will have links of e-voting service providers i.e., MUFG InTime. Click on "MUFG InTime" or "evoting link displayed alongside Company's Name" and you will be redirected to InstaVote website for casting the vote during the remote e-voting period.

Type of shareholders	Login Method
	METHOD 2 - CDSL Easi/ Easiest facility: ***Shareholders registered for Easi/ Easiest facility:*** a) Visit URL: https://web.cdslindia.com/myeasitoken/Home/Login or Visit URL: www.cdslindia.com, click on "Login" and select "My Easi New (Token)". b) Enter existing username, Password & click on "Login". c) Post successful authentication, user will be able to see e-voting option. The evoting option will have links of e-voting service providers i.e., MUFG InTime. Click on "MUFG InTime" or "evoting link displayed alongside Company's Name" and you will be redirected to InstaVote website for casting the vote during the remote e-voting period. ***Shareholders not registered for Easi/ Easiest facility:*** a) To register, visit URL: https://web.cdslindia.com/myeasitoken/Home/EasiRegistration / https://web.cdslindia.com/myeasitoken/Home/EasiestRegistration. b) Proceed with updating the required fields for registration. c) Post successful registration, user will be provided username and password on the registered email id. Follow steps given above in points (a-c).
Individual Shareholders holding securities in demat mode with Depository Participant	Individual shareholders can also login using the login credentials of your demat account through your depository participant registered with NSDL / CDSL for e-voting facility. 1. Login to DP website 2. After Successful login, user shall navigate through "e-voting" option. 3. Click on e-voting option, user will be redirected to NSDL / CDSL Depository website after successful authentication, wherein user can see e-voting feature. 4. Post successful authentication, click on "MUFG InTime" or "evoting link displayed alongside Company's Name" and you will be redirected to InstaVote website for casting the vote during the remote e-voting period.
Login method for shareholders holding securities in physical mode / Non-Individual Shareholders holding securities in demat mode.	Shareholders holding shares in physical mode / Non-Individual Shareholders holding securities in demat mode as on the cut-off date for e-voting may register and vote on InstaVote as under: **STEP 1: LOGIN / SIGNUP on InstaVote** Shareholders registered for INSTAVOTE facility: a) Visit URL: https://instavote.linkintime.co.in & click on "Login" under 'SHARE HOLDER' tab. b) Enter details as under: 1. User ID: Enter User ID 2. Password: Enter existing Password 3. Enter Image Verification (CAPTCHA) Code 4. Click "Submit". (Home page of e-voting will open. Follow the process given under "Steps to cast vote for Resolutions") **InstaVote USER ID** **NSDL**: User ID is 8 Character DP ID followed by 8 Digit Client ID (e.g.IN123456) and 8 digit Client ID (eg. 12345678). **CDSL**: User ID is 16 Digit Beneficiary ID **Shares held in physical form**: User ID is Event No + Folio no. registered with the Company

Type of shareholders	Login Method

Shareholders not registered for INSTAVOTE facility:

a) Visit URL: https://instavote.linkintime.co.in & click on "Sign Up" under 'SHARE HOLDER' tab & register with details as under:

1. User ID: Enter User ID
2. PAN: Enter your 10-digit Permanent Account Number (PAN) (Shareholders who have not updated their PAN with the Depository Participant (DP)/ Company shall use the sequence number provided to you, if applicable.
3. DOB/DOI: Enter the Date of Birth (DOB) / Date of Incorporation (DOI) (As recorded with your DP/Company - in DD/MM/YYYY format)
4. Bank Account Number: Enter your Bank Account Number (last four digits), as recorded with your DP/Company.
    - Shareholders, holding shares in NSDL form, shall provide 'point 4' above.
    - Shareholders, holding shares in CDSL form, shall provide 'point 3' or 'point 4' above.
    - Shareholders, holding shares in physical form but have not recorded 'point 3' and 'point 4', shall provide their Folio number in 'point 4' above
5. Set the password of your choice.

    (The password should contain minimum 8 characters, at least one special Character (!#$&*), at least one numeral, at least one alphabet and at least one capital letter).
6. Enter Image Verification (CAPTCHA) Code.
7. Click "Submit" (You have now registered on InstaVote).

    Post successful registration, click on "Login" under 'SHARE HOLDER' tab & follow steps given above in points (a-b).

InstaVote USER ID		
	NSDL	User ID is 8 Character DP ID followed by 8 Digit Client ID (e.g.IN123456) and 8 digit Client ID (eg. 12345678).
	CDSL	User ID is 16 Digit Beneficiary ID
	Shares held in physical form	User ID is Event No + Folio no. registered with the Company

STEP 2: Steps to cast vote for Resolutions through InstaVote

A. Post successful authentication and redirection to InstaVote inbox page, you will be able to see the "Notification for e-voting".

B. Select 'View' icon. E-voting page will appear.

C. Refer the Resolution description and cast your vote by selecting your desired option 'Favour / Against' (If you wish to view the entire Resolution details, click on the 'View Resolution' file link).

D. After selecting the desired option i.e. Favour / Against, click on 'Submit'.

E. A confirmation box will be displayed. If you wish to confirm your vote, click on 'Yes', else to change your vote, click on 'No' and accordingly modify your vote.

NOTE: Shareholders may click on "Vote as per Proxy Advisor's Recommendation" option and view proxy advisor recommendations for each resolution before casting vote. "Vote as per Proxy Advisor's Recommendation" option provides access to expert insights during the e-Voting process. Shareholders may modify their vote before final submission.

Once you cast your vote on the resolution, you will not be allowed to modify or change it subsequently.

Non-Individual Body corporate shareholders shall send a scanned copy of the board resolution authorising its representative to vote, to the scrutinizer at registered email address with a copy marked to RTA at enotices@in.mpms.mufg.com and the company at registered email address.

Guidelines for Institutional shareholders ("Custodian / Corporate Body/ Mutual Fund")

STEP 1 – Custodian / Corporate Body/ Mutual Fund Registration

A. Visit URL: https://instavote.linkintime.co.in

B. Click on "Sign Up" under "Custodian / Corporate Body/ Mutual Fund"

C. Fill up your entity details and submit the form.

D. A declaration form and organisation ID is generated and sent to the Primary contact person email ID (which is filled at the time of sign up). The said form is to be signed by the Authorised Signatory, Director, Company Secretary of the entity & stamped and sent to insta.vote@linkintime.co.in.

E. Thereafter, Login credentials (User ID; Organisation ID; Password) is sent to Primary contact person's email ID. (You have now registered on InstaVote)

STEP 2 – Investor Mapping

A. Visit URL: https://instavote.linkintime.co.in and login with InstaVote Login credentials.

B. Click on "Investor Mapping" tab under the Menu section

C. Map the Investor with the following details:

1) 'Investor ID' – Investor ID for NSDL demat account is 8 Character DP ID followed by 8 Digit Client ID i.e., IN00000012345678; Investor ID for CDSL demat account is 16 Digit Beneficiary ID.

2) 'Investor's Name - Enter Investor's Name as updated with DP.

3) 'Investor PAN' - Enter your 10-digit PAN.

4) 'Power of Attorney' - Attach Board resolution or Power of Attorney.

Click on Submit button. (The investor is now mapped with the Custodian / Corporate Body/ Mutual Fund Entity). The same can be viewed under the "Report section".

NOTE: File Name for the Board resolution/ Power of Attorney shall be – DP ID and Client ID or 16 Digit Beneficiary ID.

Further, Custodians and Mutual Funds shall also upload specimen signatures.

D. Click on Submit button. (The investor is now mapped with the Custodian / Corporate Body/ Mutual Fund Entity). The same

STEP 3 – Steps to cast vote for Resolutions through InstaVote

The corporate shareholder can vote by two methods, during the remote e-voting period.

METHOD 1 - VOTES ENTRY

a) Visit URL: https://instavote.linkintime.co.in and login with InstaVote Login credentials.

b) Click on "Votes Entry" tab under the Menu section.

c) Enter the "Event No. **260593**" for which you want to cast vote.

Event No. can be viewed on the home page of InstaVote under "On-going Events".

d) Enter "16-digit Demat Account No.".

e) Refer the Resolution description and cast your vote by selecting your desired option 'Favour / Against' (If you wish to view the entire Resolution details, click on the 'View Resolution' file link). After selecting the desired option i.e. Favour / Against, click on 'Submit'.

f) A confirmation box will be displayed. If you wish to confirm your vote, click on 'Yes', else to change your vote, click on 'No' and accordingly modify your vote.

(Once you cast your vote on the resolution, you will not be allowed to modify or change it subsequently).

METHOD 2 - VOTES UPLOAD

a) Visit URL: https://instavote.linkintime.co.in and login with InstaVote Login credentials.

b) After successful login, you will see "Notification for e-voting".

c) Select "View" icon for "Company's Name / Event number".

d) E-voting page will appear.

e) Download sample vote file from "Download Sample Vote File" tab.

f) Cast your vote by selecting your desired option 'Favour / Against' in the sample vote file and upload the same under "Upload Vote File" option.

g) Click on 'Submit'. 'Data uploaded successfully' message will be displayed.(Once you cast your vote on the resolution, you will not be allowed to modify or change it subsequently).

NOTE: Non-Individual Body corporate shareholders shall send a scanned copy of the board resolution authorising its representative to vote, to the scrutinizer at registered email address with a copy marked to RTA at enotices@in.mpms.mufg.com and the company at registered email address.

HELPDESK:

Shareholders holding securities in physical mode / Non-Individual Shareholders holding securities in demat mode:

Shareholders holding securities in physical mode / Non-Individual Shareholders holding securities in demat mode facing any technical issue in login may contact INSTAVOTE helpdesk by sending a request at enotices@in.mpms.mufg.com or contact on: - Tel: 022 – 4918 6000.

Individual Shareholders holding securities in demat mode:

Individual Shareholders holding securities in demat mode may contact the respective helpdesk for any technical issues related to login through Depository i.e., NSDL and CDSL.

Login type	Helpdesk details
Individual Shareholders holding securities in demat mode with NSDL	Members facing any technical issue in login can contact NSDL helpdesk by sending request at evoting@nsdl.co.in or call at: 022 - 4886 7000
Individual Shareholders holding securities in demat mode with CDSL	Members facing any technical issue in login can contact CDSL helpdesk by sending request at helpdesk.evoting@cdslindia.com or contact at toll free no. 1800 22 55 33

Forgot Password:

Individual Shareholders holding securities in physical mode / Non-Individual Shareholders holding securities in demat mode:

Individual Shareholders holding securities in physical mode / Non-Individual Shareholders holding securities in demat mode have forgotten the USER ID [Login ID] or Password or both then the shareholder can use the "Forgot Password" option available on: https://instavote.linkintime.co.in

- Click on "Login" under 'SHARE HOLDER' tab.
- Further Click on "forgot password?"
- Enter User ID, select Mode and Enter Image Verification code
- (CAPTCHA).
- Click on "SUBMIT".

In case Custodian / Corporate Body/ Mutual Fund has forgotten the USER ID [Login ID] or Password or both then the shareholder can use the "Forgot Password" option available on: https://instavote.linkintime.co.in

- Click on 'Login' under "Custodian / Corporate Body/ Mutual Fund" tab
- Further Click on "forgot password?"
- Enter User ID, Organisation ID and Enter Image Verification code (CAPTCHA).
- Click on "SUBMIT".

InstaVote USER ID	
NSDL	User ID is 8 Character DP ID followed by 8 Digit Client ID (e.g.IN123456) and 8 digit Client ID (eg. 12345678).
CDSL	User ID is 16 Digit Beneficiary ID
Shares held in physical form	User ID is Event No + Folio no. registered with the Company

In case Custodian / Corporate Body/ Mutual Fund has forgotten the USER ID [Login ID] or Password or both then the shareholder can use the "Forgot Password" option available on: https://instavote.linkintime.co.in

- Click on 'Login' under "Custodian / Corporate Body/ Mutual Fund" tab
- Further Click on "forgot password?"
- Enter User ID, Organisation ID and Enter Image Verification code (CAPTCHA).
- Click on "SUBMIT".

In case shareholders have a valid email address, Password will be sent to his / her registered e-mail address. Shareholders can set the password of his/her choice by providing information about the particulars of the Security Question and Answer, PAN, DOB/DOI etc. The password should contain a minimum of 8 characters, at least one special character (!#$&*), at least one numeral, at least one alphabet and at least one capital letter.

Individual Shareholders holding securities in demat mode with NSDL/ CDSL has forgotten the password:

Individual Shareholders holding securities in demat mode have forgotten the USER ID [Login ID] or Password or both, then the Shareholders are advised to use Forget User ID and Forget Password option available at above mentioned depository/ depository participants website.

General Instructions - Shareholders

❖ It is strongly recommended not to share your password with any other person and take utmost care to keep your password confidential.

❖ For shareholders/ members holding shares in physical form, the details can be used only for voting on the resolutions contained in this Notice.

❖ During the voting period, shareholders/ members can login any number of time till they have voted on the resolution(s) for a particular "Event".

25. Instructions for Shareholders/Members to Vote during the Annual General Meeting through InstaMeet: Once the electronic voting is activated by the scrutinizer/ moderator during the meeting, shareholders/members who have not exercised their vote through the remote e-voting can cast the vote as under:

    1. On the Shareholders VC page, click on the link for e-Voting, "Cast your vote"
    2. Enter your 16 digit Demat Account No. / Folio Number and OTP (received on the registered mobile number/ registered e-mail Id) received during registration for InstaMeet and click on 'Submit'.
    3. After successful login, you will see "Resolution Description" and against the same the option "Favour/Against" for voting.
    4. Cast your vote by selecting appropriate option i.e. "Favour/Against" as desired. Enter the number of shares (which represents no. of votes) as on the cut-off date under 'Favour/Against'.
    5. After selecting the appropriate option i.e. Favour/ Against as desired and you have decided to vote, click on "Save". A confirmation box will be displayed. If you wish to confirm your vote, click on "Confirm", else to change your vote, click on "Back" and accordingly modify your vote.
    6. Once you confirm your vote on the resolution, you will not be allowed to modify or change your vote subsequently.

    Note: Shareholders/ Members, who will be present in the Annual General Meeting through InstaMeet facility and have not casted their vote on the Resolutions through remote e-Voting and are otherwise not barred from doing so, shall be eligible to vote through e-Voting facility during the meeting.

    Shareholders/Members who have voted through Remote e-Voting prior to the Annual General Meeting will be eligible to attend/participate in the Annual General Meeting through InstaMeet. However, they will not be eligible to vote again during the meeting.

    Shareholders/Members are encouraged to join the Meeting through Tablets/Laptops connected through broadband for better experience.

    Please note that Shareholders/ Members connecting from Mobile Devices or Tablets or through Laptops connecting via Mobile Hotspot may experience Audio/ Visual loss due to fluctuation in their network. It is therefore recommended to use stable Wi-Fi or LAN connection to mitigate any kind of aforesaid glitches.

    In case shareholders/ members have any queries regarding login/ e-voting, they may send an email to instameet@in.mpms.mufg.com or contact on: - Tel: 022- 49186000 / 49186175.

26. INSTAMEET VC INSTRUCTIONS:

In terms of Ministry of Corporate Affairs (MCA) General Circular No. 03/2025 dated 22 September 2025, the companies can continue to conduct AGMs by VC or OAVM, as per the existing procedural requirements. Till further orders, the relaxations will remain in force.

Shareholders are advised to update their mobile number and email Id correctly in their demat accounts to access InstaMeet facility.

Login method for shareholders to attend the General Meeting through InstaMeet:

a) Visit URL: https://instameet.in.mpms.mufg.com & click on "Login".

b) Select the "Company Name" and register with your following details:

c) Select Check Box - Demat Account No. / Folio No. / PAN

- Shareholders holding shares in NSDL/ CDSL demat account shall select check box - Demat Account No. and enter the 16-digit demat account number.
- Shareholders holding shares in physical form shall select check box – Folio No. and enter the Folio Number registered with the company.
- Shareholders shall select check box – PAN and enter 10-digit Permanent Account Number (PAN). Shareholders who have not updated their PAN with the Depository Participant (DP)/ Company shall use the sequence number provided by MUFG Intime, if applicable.
- Mobile No: Mobile No. as updated with DP is displayed automatically. Shareholders who have not updated their Mobile No with the DP shall enter the mobile no.
- Email ID: Email Id as updated with DP is displayed automatically. Shareholders who have not updated their Email Id with the DP shall enter the Email Id.

d) Click "Go to Meeting"

You are now registered for InstaMeet, and your attendance is marked for the meeting.

27. INSTRUCTIONS FOR SHAREHOLDERS TO SPEAK DURING THE GENERAL MEETING THROUGH INSTAMEET:

a) Shareholders who would like to speak during the meeting must register their request with the company at company's registered email address.

b) Shareholders will get confirmation on first cum first basis depending upon the provision made by the company.

c) Shareholders will receive "speaking serial number" once they mark attendance for the meeting. Please remember speaking serial number and start your conversation with panellist by switching on video mode and audio of your device.

d) Other shareholder who has not registered as "Speaker Shareholder" may still ask questions to the panellist via active chat-board during the meeting.

*Shareholders are requested to speak only when moderator of the meeting/ management will announce the name and serial number for speaking.

28. INSTRUCTIONS FOR SHAREHOLDERS TO VOTE DURING THE GENERAL MEETING THROUGH INSTAMEET:

Once the electronic voting is activated during the meeting, shareholders who have not exercised their vote through the remote e-voting can cast the vote as under:

a) On the Shareholders VC page, click on link "Cast your vote".

b) Enter your 16-digit Demat Account No. / Folio No. and OTP (received on the registered mobile number/ registered email Id) received during registration for InstaMeet.

c) Click on 'Submit'.

d) After successful login, you will see "Resolution Description" and against the same the option "Favour/ Against" for voting.

e) Cast your vote by selecting appropriate option i.e. "Favour/Against" as desired. Enter the number of shares (which represents no. of votes) as on the cut-off date under 'Favour/Against'.

f) After selecting the appropriate option i.e. Favour/ Against as desired and you have decided to vote, click on "Save". A confirmation box will be displayed. If you wish to confirm your vote, click on "Confirm", else to change your vote, click on "Back" and accordingly modify your vote. Once you confirm your vote on the resolution, you will not be allowed to modify or change your vote subsequently.

Note:

Shareholders/ Members, who will be present in the General Meeting through InstaMeet facility and have not casted their vote on the Resolutions through remote e-Voting and are otherwise not barred from doing so, shall be eligible to vote through e-Voting facility during the meeting.

Shareholders/ Members who have voted through Remote e-Voting prior to the General Meeting will be eligible to attend/ participate in the General Meeting through InstaMeet. However, they will not be eligible to vote again during the meeting.

Shareholders/ Members are encouraged to join the Meeting through Tablets/ Laptops connected through broadband for better experience.

Shareholders/ Members are required to use Internet with a good speed (preferably 2 MBPS download stream) to avoid any disturbance during the meeting.

Please note that Shareholders/ Members connecting from Mobile Devices or Tablets or through Laptops connecting via Mobile Hotspot may experience Audio/Visual loss due to fluctuation in their network. It is therefore recommended to use stable Wi-FI or LAN connection to mitigate any kind of aforesaid glitches.

Helpdesk:

Shareholders facing any technical issue in login may contact INSTAMEET helpdesk by sending a request at instameet@in.mpms.mufg.com or contact on: - Tel: 022 – 4918 6000 / 4918 6175.

29. The voting rights of Members shall be in proportion to their shares of the total paid up equity share capital of the Company as on the cut-off date.

30. In case of joint holders attending the Meeting, only such joint holder who is higher in the order of names shall be entitled to vote.

31. Any person, who acquires shares of the Company and becomes Member of the Company after sending the Notice of the Meeting and holding shares as of the cut-off date needs to refer to the instruction above regarding login ID and password and may contact the Company or RTA for any query or assistance in this regard. Any person who is not a Member as on the cut-off date should treat this Notice for information purposes only.

32. The Members who have cast their vote by remote e-voting prior to the AGM may also attend the AGM through VC/OAVM but shall not be entitled to cast their vote again or change it subsequently.

33. Only those Members, whose names are recorded in the Register of Members or in the Register of Beneficial Owners maintained by the Depositories as on the cut-off date shall be entitled to avail the facility of remote e-voting as well as e-voting at the AGM.

34. Non-Resident Indian Members are requested to inform RTA, immediately on change in their residential status on return to India for permanent settlement, and update on particulars of their bank account maintained in India with complete name, branch, account type, account number and address of the bank with PIN Code number, if not furnished earlier.

By the Order of the Board
Medicamen Biotech Limited

Sd/-
Rahul Bishnoi
Chairman
DIN-00317960

Place: New Delhi
Date: 14 August 2026

STATEMENT SETTING OUT ALL MATERIAL FACTS CONCERNING EACH OF THE BUSINESS(ES) TO BE TRANSACTED AT THE THIRTY THIRD ANNUAL GENERAL MEETING AS STATED IN THE NOTICE DATED 14 AUGUST 2026

[Pursuant to Section 102 of the Companies Act, 2013]

Item Nos. 1 and 2: Ordinary Resolution

As per the applicable statutory provisions, the Company submits its standalone and consolidated financial statements for the financial year for adoption by members at the AGM.

The Board of Directors ('Board'), on the recommendation of the Audit Committee, has approved the standalone and consolidated financial statements for the financial year ended 31 March 2026.

The standalone and consolidated financial statements of the Company along with the reports of the Board and Statutory Auditors' thereon have been:

a. sent to the members at their registered email address; and

b. uploaded on the website of the Company, i.e. www.medicamen.com under the 'Investors Section'.

The Board confirms compliance with applicable accounting standards in preparation of the financial statements, adoption of consistent and prudent accounting policies, maintenance of adequate records and internal financial controls, and preparation of accounts on a going concern basis, thereby presenting a true and fair view of the Company's financial position and performance.

The Statutory Auditor has issued unmodified reports on the financial statements and has confirmed that both standalone and consolidated financial statements represent the true and fair view of the state of affairs of the Company.

In case members have any query or question on the financial statements, they are requested to send their queries or questions to the Company Secretary at the email id cs@medicamen.com to enable the management to objectively respond to these queries at the AGM.

The Board recommends the resolutions as set out in item nos. 1 and 2 for approval by the members as ordinary resolutions. None of the directors and the key managerial personnel and/ or their relatives are in any way, financially or otherwise, interested or concerned in these resolutions.

Item No. 3: Ordinary Resolution

As per the applicable statutory provisions, the dividend is required to be declared by the members of the Company, on the recommendation of the Board.

In accordance with the Dividend Distribution Policy of the Company, the Board has recommended a final dividend of ₹ 1/- per equity share (i.e. 10% on the face value of 10/-), for the financial year ended on 31 March 2026. In case the shares are held in physical form, the dividend recommended by the Board, if approved, will be paid to those members whose name will appear in the Register of Members on the record date i.e., as at the close of business hours on Saturday, 19 September 2026 and in respect of shares held in dematerialised form, the dividend will be paid to the beneficial owners whose name appears in the Register of Beneficial Owners as per the records of the National Securities Depository Limited and the Central Depository Services (India) Limited as on Saturday, 19 September 2026.

The Company will endeavour to pay the dividend within 7 working days from the date of the declaration but not later than 30 days from the date of the ensuing AGM.

The Board recommends the resolution as set out in item no. 3 for approval by the members as an ordinary resolution.

None of the directors and the key managerial personnel and/ or their relatives are in any way, financially or otherwise, interested or concerned in this resolution except as a member to the extent of their shareholding in the Company.

Item No. 4: Ordinary Resolution

As per the applicable statutory provisions, at least two-thirds of the total number of directors (excluding independent directors), are liable to retire by rotation, out of which one-third of the total number of such directors shall retire at every AGM.

In compliance with this requirement, Mr Suresh Kumar Singh, Non-Executive Director of the Company, is liable to retire by rotation and being eligible, has offered himself for re-appointment.

Mr S. K. Singh is a Chemical Engineer with over 30 years rich experience of running chemical units. He has served as a Production Controller at M/s Synthetics and Chemicals Limited for approximately 12 years. He is responsible for running agrochemical unit of Shivalik Rasayan at Dehradun.

Detailed profile of Mr Suresh Kumar Singh is also available on the website of the Company at www.medicamen.com in the 'Investors Section'. Details as required under Regulations 36(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Secretarial Standard – 2 and other applicable provisions have been provided in **Annexure I** to the explanatory statement.

Based on the performance evaluation of Mr Suresh Kumar Singh, the Board recommends the resolution as set out in item no. 4 for approval by the members as an ordinary resolution.

Item No. 5: Ordinary Resolution

As per the applicable statutory provisions, at least two-thirds of the total number of directors (excluding independent directors), are liable to retire by rotation, out of which one-third of the total number of such directors shall retire at every AGM.

In compliance with this requirement, Mr Sanjay Bansal, Non-Executive Director of the Company, is liable to retire by rotation and being eligible, has offered himself for re-appointment.

Mr Sanjay Bansal has rich experience of over 30 years in the field of finance, investments, taxation and international trade. He has extensively travelled across the globe and has attained exposure to various industries, including pharma. He has been the Director of Medicamen Biotech Limited, since inception and has been sharing his valuable insights for the betterment of the Company.

Detailed profile of Mr Sanjay Bansal is also available on the website of the Company at www.medicamen.com in the 'Investors Section'. Details as required under Regulations 36(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Secretarial Standard – 2 and other applicable provisions have been provided in **Annexure I** to the explanatory statement.

Based on the performance evaluation of Mr Sanjay Bansal, the Board recommends the resolution as set out in item no. 5 for approval by the members as an ordinary resolution.

Item No. 6: Ordinary Resolution

The Board, on the recommendation of the Audit Committee, has re-appointed M/s SPB & Co – Cost Accountants (Firm Registration No. 102586) as the Cost Auditor to audit the ₹ 2,00,000/- (Rupees Two Lakhs Only) plus applicable taxes and reimbursement of reasonable out-of-pocket expenses.

As per the statutory provision, the remuneration payable to the cost auditor is required to be ratified by the members of the Company.

The Board recommends the resolution as set out in item no. 6 for ratification by the members as an ordinary resolution.

None of the directors and the key managerial personnel and/ or their relatives are in any way, financially or otherwise, interested or concerned in this resolution.

Item No. 7:

Approval of Material Related Party Transactions with Shivalik Rasayan Limited

Shivalik Rasayan Limited ("SRL") is the Holding Company of Medicamen Biotech Limited ("the Company") and is a Related Party within the meaning of Section 2(76) of the Companies Act, 2013 ("Act") and Regulation 2(1)(zb) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations").

The Company is engaged in the business of manufacturing and marketing pharmaceutical formulations, including general pharmaceutical products, oncology products and other speciality formulations. The manufacturing of such formulations requires continuous procurement of Active Pharmaceutical Ingredients ("APIs"), which constitute the principal raw materials for the Company's products.

SRL is engaged, inter alia, in the manufacture of APIs and specialty chemicals and possesses established manufacturing facilities, technical expertise and research and development capabilities. In the ordinary course of business, the Company procures APIs from SRL and also avails research and development support, technical assistance, process optimisation services and other related business support required for manufacturing pharmaceutical formulations.

Considering the projected increase in business operations, product portfolio expansion and anticipated procurement requirements during 2026-27, the aggregate value of transactions proposed to be entered into with SRL is expected to exceed the materiality threshold prescribed under Regulation 23 of the SEBI Listing Regulations. Accordingly, approval of the Members is being sought by way of an Ordinary Resolution.

The proposed transactions are intended to ensure uninterrupted availability of quality APIs, leverage the manufacturing and research capabilities available within the Group, improve operational efficiencies, optimise costs and strengthen the Company's manufacturing operations. The proposed transactions are expected to be undertaken in the ordinary course of business and on an arm's length basis.

The pricing and commercial terms of the proposed transactions shall be determined based on prevailing market prices, comparable uncontrolled prices, product specifications, quantity, commercial negotiations and other generally accepted commercial parameters applicable to similar transactions with unrelated parties.

The Audit Committee has reviewed the proposed transactions, including the nature of the transactions, business rationale, pricing methodology, commercial terms, necessity, materiality and overall benefit expected to accrue to the Company, and has recommended the same to the Board of Directors.

The Board of Directors, after considering the recommendation of the Audit Committee, is of the opinion that the proposed Material Related Party Transactions are in the ordinary course of business, are at arm's length, are commercially beneficial and are in the best interests of the Company and its shareholders. Accordingly, the Board recommends the Ordinary Resolution set out at Item No. 7 for approval by the Members.

The approval of the Members shall remain valid for transactions undertaken from the date of approval until the conclusion of the next Annual General Meeting or one year from the date of approval, whichever is earlier.

In accordance with Regulation 23 of the SEBI Listing Regulations, all Related Parties, irrespective of whether they are parties to the proposed transactions or not, shall abstain from voting on the Resolution.

Except to the extent of their shareholding, directorship or other interest in Shivalik Rasayan Limited, if any, none of the Directors, Key Managerial Personnel of the Company or their relatives is concerned or interested, financially or otherwise, in the Resolution.

Additional Information pursuant to Regulation 23 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and the SEBI Master Circular dated 30 January 2026

Particulars	Details
Name of the Related Party	Shivalik Rasayan Limited
Relationship with the Company	Holding Company
Nature of Related Party Transactions	Procurement of Active Pharmaceutical Ingredients (APIs), Research & Development Support, Technical Support, Product Development, Process Optimization and Other Business Support/Services
Nature of Material Transaction	Purchase/Sale of goods and availing of services
Tenure of Approval	From the date of Members' approval until the conclusion of the next AGM or one year from the date of approval, whichever is earlier
Maximum Aggregate Value of Transactions	₹30.00 Crores
Actual Value of Transactions during 2025-26	₹1,352.89 Lakhs
Annual Consolidated Turnover of the Company (2025-26)	₹19,776.97 Lakhs
Percentage of Annual Consolidated Turnover represented by the proposed transactions	Approximately **15.17%**
Whether in Ordinary Course of Business	Yes
Whether on Arm's Length Basis	Yes
Pricing Methodology	Based on prevailing market prices, comparable uncontrolled prices, commercial quotations, negotiated contractual terms and other generally accepted commercial parameters
Business Rationale and Benefit	To ensure uninterrupted procurement of APIs, utilise the Group's R&D capabilities, improve manufacturing efficiencies, optimise procurement costs and support business growth
Audit Committee Recommendation	The Audit Committee has reviewed and recommended the proposed transactions to the Board.
Board Recommendation	The Board recommends the Resolution for approval by the Members.
Voting Restriction	All Related Parties shall abstain from voting on the Resolution in accordance with Regulation 23 of the SEBI Listing Regulations.

Item No. 8:

Approval of Material Related Party Transactions with Medicamen Life Sciences Private Limited

Medicamen Life Sciences Private Limited ("MLSPL") is a Subsidiary of Medicamen Biotech Limited ("the Company") and is a Related Party within the meaning of Section 2(76) of the Companies Act, 2013 ("Act") and Regulation 2(1)(zb) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations").

The Company is engaged in the business of manufacturing and marketing pharmaceutical formulations, including general pharmaceutical products, oncology products and other speciality formulations. MLSPL is engaged in the business of marketing, distribution and trading of pharmaceutical products.

As part of the Group's integrated business operations, the Company supplies pharmaceutical formulations manufactured by it to MLSPL, which undertakes marketing, trading and distribution of such products in domestic and international markets. The proposed transactions are integral to the Company's business model and facilitate optimum utilisation of manufacturing capacity, improved market penetration, operational efficiencies and better customer service.

Considering the projected growth in business operations during the Financial Year 2026-27, the aggregate value of transactions proposed to be entered into with MLSPL is expected to exceed the materiality threshold prescribed under Regulation 23 of the SEBI Listing Regulations. Accordingly, prior approval of the Members is being sought by way of an Ordinary Resolution.

The proposed transactions are expected to be undertaken in the ordinary course of business and on an arm's length basis. The pricing and commercial terms shall be determined having regard to prevailing market prices, comparable uncontrolled prices, product specifications, commercial negotiations, volume commitments and other generally accepted commercial parameters applicable to similar transactions with unrelated parties.

The Audit Committee has reviewed the proposed transactions, including the nature of the transactions, commercial rationale, pricing methodology, necessity, materiality and expected benefits to the Company and has recommended the same to the Board of Directors.

The Board of Directors, after considering the recommendation of the Audit Committee, is of the opinion that the proposed Material Related Party Transactions are in the ordinary course of business, are on an arm's length basis and are in the best interests of the Company and its shareholders. Accordingly, the Board recommends the Ordinary Resolution set out at Item No. 8 for approval by the Members.

The approval of the Members shall remain valid for transactions undertaken from the date of approval until the conclusion of the next Annual General Meeting of the Company or one year from the date of approval, whichever is earlier.

In accordance with Regulation 23 of the SEBI Listing Regulations, all Related Parties of the Company shall abstain from voting on the Resolution irrespective of whether they are parties to the proposed transactions.

Except to the extent of their shareholding, directorship or other interest, if any, in MLSPL, none of the Directors, Key Managerial Personnel of the Company or their relatives is concerned or interested, financially or otherwise, in the Resolution.

Additional Information pursuant to Regulation 23 of the SEBI Listing Regulations and the SEBI Master Circular dated 30 January 2026

Particulars	Disclosure
Name of Related Party	Medicamen Life Sciences Private Limited
Relationship	Subsidiary Company
Nature of Transaction	Sale and supply of pharmaceutical products, trading, marketing and distribution support and other operational transactions
Nature of Material Transaction	Sale of goods and rendering/availing of services/advance paid/ reimbursement of expenses
Tenure of Approval	From the date of Members' approval until the conclusion of the next AGM or one year from the date of approval, whichever is earlier
Maximum Aggregate Value	₹30.00 Crores
Actual Value of Transactions during 2025-26	**₹ 184.77 Lakhs**
Annual Consolidated Turnover of the Company (2025-26)	₹19,776.97 Lakhs
Percentage of Annual Consolidated Turnover represented by the proposed transactions	Approximately **15.17%**
Whether in Ordinary Course of Business	Yes
Whether on Arm's Length Basis	Yes
Pricing Methodology	Market price, comparable uncontrolled price, negotiated commercial terms and other accepted transfer pricing parameters
Business Rationale	To strengthen the Group's marketing and distribution network, optimise manufacturing capacity, improve operational efficiencies and enhance market reach

Particulars	Disclosure
Audit Committee Recommendation	The Audit Committee has reviewed and recommended the proposed transactions.
Board Recommendation	The Board recommends the Resolution for approval by the Members.
Voting Restriction	All Related Parties shall abstain from voting in accordance with Regulation 23 of the SEBI Listing Regulations.

ANNEXURE-I

PROFILE OF DIRECTOR

[Pursuant to Regulation 36(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Secretarial Standard – 2 on General Meetings]

Full Name	Mr Suresh Kumar Singh
Director Identification Number (DIN)	00318015
Age	81
Date of first appointment on the Board	31 December 2015
Qualification	Chemical Engineer
Experience and nature of expertise in specific functional areas / Brief resume	Mr S. K. Singh is a Chemical Engineer with over 30 years rich experience of running chemical units. He has served as a Production Controller at M/s Synthetics and Chemicals Limited for approximately 12 years. He is responsible for running agrochemical unit of Shivalik Rasayan at Dehradun.
Remuneration last drawn (including sitting fees)	NA
Remuneration to be paid	NA
Number of board meetings attended during 2025-26	Two
Terms and conditions of re-appointment	In terms of the provisions of Section 152 of the Companies Act, 2013 ("the Act") at least two-thirds of the total number of directors (excluding independent directors), are liable to retire by rotation, out of which at least one-third of the total number of such directors shall retire at every AGM. In accordance with the said requirement, Mr Suresh Kumar Singh, Non-Executive Director of the Company, would be retiring at this AGM and being eligible, has offered himself for reappointment.
Shareholding including shareholding as beneficial owner (Equity Shares)	Nil
Member/ Chairperson of committees of the Company	Corporate Social Responsibility Committee- Member
Directorships held in other companies	One
Relationship with other directors and key managerial personnel	NA
Chairperson and Membership of committees held in other Indian companies	Corporate Social Responsibility Committee- Chairperson (Shivalik Rasayan Limited)
Listed entities from which the person has resigned in the past three years	NA

PROFILE OF DIRECTOR

[Pursuant to Regulation 36(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Secretarial Standard – 2 on General Meetings]

Full Name	Mr Sanjay Bansal
Director Identification Number (DIN)	00121667
Age	62
Date of first appointment on the Board	27 February 2016
Qualification	Chartered Accountant (CA)
Experience and nature of expertise in specific functional areas / Brief resume	Mr Sanjay Bansal has rich experience of over 30 years in the field of finance, investments, taxation and international trade. He has extensively travelled across the globe and has attained exposure to various industries, including pharma. He has been the Director of Medicamen Biotech Limited, since inception and has been sharing his valuable insights for the betterment of the Company.
Remuneration last drawn (including sitting fees)	NA
Remuneration to be paid	NA
Number of board meetings attended during 2025-26	Five
Terms and conditions of re-appointment	In terms of the provisions of Section 152 of the Companies Act, 2013 ("the Act") at least two-thirds of the total number of directors (excluding independent directors), are liable to retire by rotation, out of which at least one-third of the total number of such directors shall retire at every AGM. In accordance with the said requirement, Mr Sanjay Bansal, Non- Executive Director of the Company, would be retiring at this AGM and being eligible, has offered himself for reappointment.
Shareholding including shareholding as beneficial owner (Equity Shares)	102813
Member/ Chairperson of committees of the Company	Corporate Social Responsibility Committee- Member
Directorships held in other companies	Six (One Listed and Five Unlisted Pvt Co.'s)
Relationship with other directors and key managerial personnel	NA
Chairperson and Membership of committees held in other Indian companies	Corporate Social Responsibility Committee- Member (Shivalik Rasayan Limited)
Listed entities from which the person has resigned in the past three years	One (Shivalik Rasayan Limited) as on 27 May 2026

Notes

Notes

Notes

MEDICAMEN BIOTECH LIMITED

Registered Office
1506, Chiranjiv Tower 43
Nehru Place, New Delhi – 110 019
Tel: 011 4758 9500
Website: www.medicamen.com

Haridwar Unit-I: 86 and 87, Sector-6A, IIE,
SIDCUL, BHEL, Ranipur,
Haridwar – 249 403, Uttarakhand

Bhiwadi Factory
SP-1192A and B Phase-IV,
Industrial Area, Bhiwadi – 301 019,
District: Alwar, Rajasthan

Haridwar Unit-II: 84 and 85, Sector-6A, IIE,
SIDCUL, BHEL, Ranipur,
Haridwar – 249 403, Uttarakhand